The differential effects of neuroleptic drugs and PACAP on the expression of BDNF mRNA and protein in a human glioblastoma cell line by Jóźwiak‑Bębenista, Marta et al.
©
 20
17
 b
y A
ct
a N
eu
ro
bi
olo
gi
ae
 Ex
pe
rim
en
ta
lis
The differential effects of neuroleptic drugs  
and PACAP on the expression of BDNF mRNA  
and protein in a human glioblastoma cell line
Marta Jóźwiak‑Bębenista1*, Magdalena Jasińska‑Stroschein2, and Edward Kowalczyk1
1Department of Pharmacology and Toxicology, The Interfaculty Chair of Basic and Clinical Pharmacology and Toxicology,  
Medical University of Lodz, Poland, 2Department of Biopharmacy, Medical University of Lodz, Poland,  
* Email: marta.jozwiak‑bebenista@umed.lodz.pl
It has been suggested that, in addition to modulation of monoaminergic neurotransmission, antipsychotic drugs can also affect expression 
of neurotrophic factors in the brain. The present study was aimed to examine the effects of the first generation neuroleptic drug (FGA; 
haloperidol) and second generation neuroleptic drugs (SGAs; olanzapine and amisulpride) on expression and level of brain-derived 
neurotrophic factor (BDNF) in astrocyte-like T98G glioblastoma cell line. Effects of these drugs were compared to the action of PACAP38, 
a neuropeptide with well known BDNF-mediated neuroprotective effects. The tested neuroleptics differentially regulated the mRNA 
expression and protein level of BDNF depending on the concentration and incubation time. Using rtPCR technique, we demonstrate 
that, from the three tested neuroleptics, both haloperidol as well as olanzapine at 5 μM concentration (but not at 20 μM) increased BDNF 
mRNA expression with a similar efficacy after a 72 h incubation. In order to confirm the observed changes in the mRNA expression of 
BDNF, a protein expression assay was performed. The exposure of cells only to 5 μM olanzapine for 72 h increased BDNF concentration in 
the culture medium by 29%. Additionally, PACAP significantly up-regulated BDNF mRNA expression in T98G cells and the obtained results 
correlated positively with the increased production of BDNF protein, by 22% above control. The results of the paper show that olanzapine, 
similarly to exogenous PACAP38, increased BDNF mRNA expression and protein release, which can contribute to its neuroprotective 
mechanism of action in the cells of nonneuronal origin. The results of the present paper confirm the findings that BDNF may represent 
the key target for olanzapine and PACAP.
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INTRODUCTION
Schizophrenia is a common neuropsychiatric disor‑
der affecting 0.5‑1% of the general population world‑
wide. The disease is characterized by a profound dis‑
ruption in cognition and emotion, affecting the most 
fundamental human attributes: language, thought, 
perception, affect, and the sense of self (Cohen et al. 
2015, Tsapakis et al. 2015). The pathophysiology of 
schizophrenia is still not clear; it includes complex 
genetic and environmental interactions that impair 
neurodevelopmental processes. It has been suggested 
that disruptions in neurotrophin function, which play 
important roles in neurodevelopment and neuropro‑
tection, may have an impact on etiology of the disor‑
der. One neurotrophin whose signaling is altered in 
a schizophrenic patient is brain‑derived neurotrophic 
factor (BDNF) (Ratajczak et al. 2015). BDNF is the most 
abundant neurotrophin in the brain involved in the de‑
velopment of the nervous system (Bramham and Mes‑
saoudi 2005, Paczkowska et al. 2015), and it has been 
shown that BDNF increases neuronal survival by pro‑
tecting adult neurons from ischemic (Beck et al. 1994), 
glutamatergic (Mattson et al. 1995), and hypoglycemic 
insults (Mattson et al. 1993). Studies show that BDNF is 
abnormally regulated in animal models of schizophre‑
nia and is reduced in the plasma, CSF and postmortem 
brains of patients with schizophrenia (Durany and 
Thome, 2004, Tan et al. 2005, Pillai et al. 2010). There‑
fore, the up‑regulation of the level of the neurotrophic 
factor like BDNF might be a new approach to treat such 
psychiatric states as schizophrenia.
Current antipsychotic drugs improve the symptoms 
of schizophrenia through complex mechanisms that 
are not completely understood (de Bartolomeis et al. 
2015, Dold et al. 2015, Kusumi et al. 2015). It is known 
that they act through the modulation of monoamin‑
ergic neurotransmission, primarily involving the do‑
Research paper
Acta Neurobiol Exp 2017, 77: 205–213
Correspondence should be addressed to M. Jóźwiak‑Bębenista 
Email: marta.jozwiak‑bebenista@umed.lodz.pl
Received 9 May 2017, accepted 26 June 2017
2_Jozwiak-Bebenista_v6.indd   205 27/10/17   22:29
206 M. Jóźwiak-Bębenista et al. Acta Neurobiol Exp 2017, 77: 205–213
paminergic pathways (Seeman 2002). Recent studies 
have suggested that the action of neuroleptic drugs 
is mediated by their regulatory influence, not only 
upon small‑molecule neurotransmitters, but also via 
neurotrophic factors. Several studies have reported 
the differential effects of antipsychotics on BDNF lev‑
els in both schizophrenia subjects and animal models 
of schizophrenia (Angelucci et al. 2005, Angelucci et 
al. 2000, Chlan‑Fourney et al. 2002, Parikh et al. 2004, 
Pandya et al. 2013). These differences might be relat‑
ed to the different therapeutic effects observed for the 
first generation neuroleptic drugs (FGAs) and second 
generation antipsychotic drugs (SGAs) in patients with 
schizophrenia. However, besides neurons, little infor‑
mation is present on the modulation of BDNF by neu‑
roleptics at the mRNA and protein levels in other cell 
types of CNS. Glial cells are able to store and release 
BDNF (Hutchinson et al. 2009), and it has been suggest‑
ed that glial dysfunction may contribute to the patho‑
physiology of schizophrenia (Bernstein et al. 2015, 
Steffek et al. 2008).
Therefore, the aim of the current paper is to com‑
pare the effect of haloperidol (FGAs), olanzapine and 
amisulpride (SGAs) on the expression of BDNF mRNA 
and protein from astrocyte‑like model T98G glioblas‑
toma cells. The study uses the T98G human cell line, 
which shares many features with primary astrocytes; 
it has been widely used in astrocyte research, success‑
fully and in our research group (Avila Rodriguez et 
al. 2014, de Joannon et al. 2000, Cabezas et al. 2015). 
Additionally, the pituitary adenylate cyclase‑activat‑
ing polypeptide (PACAP) was used as a reference. It 
is a known pleiotropic neuropeptide with strong BD‑
NF‑mediated neuroprotective potential (Frechilla et el. 
2001, Jozwiak‑Bebenista et al. 2015). For the purposes 
of comparison, the effect of exogenous PACAP on the 
expression of BDNF mRNA and secretion were also eval‑
uated in this cell model. 
MATERIALS AND METHODS
Cell Cultures
The T98G glioma cell line was purchased from the 
American Type Culture Collection (ATCC; Rockville, MD, 
USA). The cells were cultured in 25‑mL flasks in a me‑
dium composed of Advanced MEM supplemented with 
10% fetal bovine serum, 2 mM glutamine and a penicil‑
lin‑streptomycin solution, in a humidified atmosphere 
of 95% air and 5% CO2 at 37°C. For subcultures, cells were 
harvested every third day in trypsin‑EDTA (0.25% tryp‑
sin, 1 mM EDTA) solution. For the gene expression as‑
say, T98G cells were plated onto six‑well plates (Nunc) 
at a density of 3 x 105 cells per well. For the BDNF en‑
zyme‑linked immunosorbent assay (ELISA), the cells 
were seeded onto 24‑well plates, at a density of 2.5 x 
105 cells per well. The following substances were used: 
fetal bovine serum, penicillin‑streptomycin solution 
(5,000 units/ml penicillin and 5,000 g/ml streptomycin 
sulphate in normal saline), phosphate buffered saline 
(PBS; pH 7.4) and trypsin‑EDTA; all were purchased from 
Invitrogen (Carlsbad, CA, USA). Advanced MEM was ob‑
tained from Gibco (Paisley, Scotland, UK).
Drug and Peptide Treatments
T98G cells were treated with the neuroleptic drugs hal‑
operidole, olanzapine, amisulpride (Sigma Chemical Co., St. 
Louis, Mo., USA), and with the peptide PACAP38 (H‑8430, 
Bachem) and incubated for 24 and 72 hours. All the neu‑
roleptic drugs were initially dissolved in dimethyl sulfox‑
ide (DMSO; Sigma‑Aldrich, St. Louis, Mo., USA) followed by 
a preparation of working concentrations in an appropriate 
medium. Control samples were treated with medium incor‑
porating DMSO in amounts corresponding to the concen‑
tration of the used drugs. As PACAP38 was dissolved in wa‑
ter, the control group consisted of just the medium without 
the peptide.
Total RNA extraction and cDNA generation
Total RNA extraction was carried out using the RNeasy 
Mini kit (Qiagen) according to the manufacturer’s instruc‑
tions. RNA content was measured using a PicoDrop spec‑
trophotometer (Picodrop Limited). The quality of RNA 
samples was analyzed by measuring the absorption ratio at 
260/280 nm. The purified total RNA was immediately used 
for cDNA synthesis or stored at ‑800C. 
cDNA was generated with QuantiTect Reverse Tran‑
scription Kit (Qiagen) according to the manufacturer’s pro‑
tocol. Samples of 1 μg of  total RNA were used as starting 
material, and reverse transcription was performed in the 
conditions optimized for use with the kit (42°C for 30 min‑
utes, 95°C for 3 minutes). The cDNA samples were kept fro‑
zen at ‑20°C.
Real‑Time PCR 
Gene expression was measured using the TaqMan 
kit.  Briefly,  the  reactions  were  performed  in  10  μl 
amounts  including 50 ng cDNA, 5 μl KAPA PROBE FAST 
qPCR Kit Master Mix ABI Prism (Kapa Biosystems) 
and  0.5  μl  appropriate  TaqMan  Gene  Expression  Assay 
(20x). Specific pre‑made TaqMan assays were used in 
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this study: brain‑derived neurotrophic factor (BDNF, 
Hs02718934_s1) and beta actin (ACTB, Hs01060665_g1) 
as the endogenous control. TaqMan PCR assays were 
performed on a 7900HT Fast Real‑Time PCR System (Ap‑
plied Biosystems) in FastGene Fast 96‑well PCR plates 
(Nippon Genetics Europe GmbH). The following thermal 
cycling specifications were performed: 20 s at 95°C and 
40 cycles each for 3 s at 95°C and 30 s at 60°C. Real‑time 
PCR data was analyzed using the 2‑ΔΔCt method (Schmitt‑
gen and Livak 2008).
ELISA assay
BDNF protein levels in the cell‑conditioned media were 
determined using a BDNF ELISA kit, according to the man‑
ufacturer`s instructions (SunRed Biotechnology Company, 
Baoshan District, Shanghai). Data is given as pg/ml protein. 
Data analysis
Analyses were conducted using Statistica 13.1 Software 
(StatSoft, Tulsa, Okla., USA). Data was expressed as mean 
± standard error of the mean (SEM) values. The variables 
were analyzed using two‑way analysis of variance (ANO‑
VA) for repeated measures (time of incubation) followed 
by a post hoc Student‑Newman‑Keul’s test. These analyses 
made it possible to evaluate statistically significant alter‑
ations in mRNA and protein level of BDNF as a function of 
treatment, and time of incubation. If necessary, the data 
was transformed to fulfill assumptions of linearity and ho‑
mogeneity of variance. A two‑tailed p‑value less than 0.05 
was  regarded as  statistically  significant  and was used  for 
these statistical analyses.
RESULTS
Effects of neuroleptics on BDNF expression  
in the T98G cell line
Three  antipsychotic  drugs with different mechanisms 
of action were chosen: FGA, represented by haloperidol, 
and two SGAs, represented by olanzapine and amisulpride. 
The astrocyte‑like model T98G glioblastoma cells were in‑
cubated with 5 and 20 µM haloperidol or olanzapine and 
with 20 and 100 µM amisulpride for 24 or 72 hours. After 
the incubation period, the total RNA was extracted and 
subjected to gene expression studies. The mRNA expres‑
sion of BDNF was differentially regulated by the tested neu‑
roleptics in T98G glioblastoma cells.
The results of the 24‑hour and 72‑hour incubation with 
three different interventions (5 µM haloperidol, 5 µM olan‑
zapine and 100 µM amisulpride) were subjected to two‑way 
ANOVA analysis. The statistical analysis revealed that time 
of incubation (24 vs. 72 hours) had a significant impact on 
the final outcome (F=16.111; df=1; p=0.00045). A significant 
relationship was also found between time of incubation 
and  type of  intervention used  (F=5.868;  df=3; p  =0.00336): 
the BDNF  expression was  significantly higher at  72 hours 
than 24 hours following haloperidol (p=0.01849) and olan‑
zapine treatment (p=0.00213). Post hoc analysis demonstrat‑
ed also that after 72‑hour incubation, both 5 µM of haloper‑
idol (p=0.02784)  and  olanzapine  (p=0.03119)  significantly 
up‑regulated BDNF mRNA expression to 1.48 and 1.54 of the 
expression status, respectively; however, 100 µM amisul‑
pride was not found to have any effect on BDNF expression 
after 24‑hour and 72‑hour incubation (Fig. 1A). 
No statistically significant changes in BDNF expression 
were observed for 20 µM haloperidol, olanzapine or ami‑
sulpride. However, after 72‑hour incubation, 20 µM amisul‑
Fig. 1. The effects of haloperidol (5 and 20 µM), olanzapine (5 and 20 µM) and amisulpride (20 and 100 µM) on BDNF expression in the T98G cell line. 
Cells were incubated with neuroleptic drugs for 24 hours or 72 hours and subjected to gene expression studies (A and B). Control cells were treated 
with medium. 1 µg of total RNA isolated from cells was reverse transcribed and 50 ng of cDNA was used for the real-time PCR analysis. All real-time 
PCR reactions were performed in duplicate, using the ACTB gene as an endogenous normalization factor. Results are expressed as relative units (r.u.) – 
a number resulting from the normalization procedure; values are given as mean ± SEM (n=4-8). Statistical differences are shown as * at p<0.05 vs. control 
and # at p<0.05 vs. 24 hours; ## at p<0.005 vs. 24 hours (Two-way ANOVA interaction: p<0.005).
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pride mildly decreased BDNF expression to 0.81 of the orig‑
inal status, similarly to 20 µM haloperidol. This observed 
effect was not maintained by 100 µM of  amisulpride  and 
the results were not statistically significant (Fig. 1B).
Effect of PACAP38 on BDNF expression  
in the T98G cell line
The effect of exogenous PACAP38 on BDNF gene ex‑
pression was also evaluated in T98G cells treated with 
1 µM PACAP38 for 24 hours or 72 hours. 
Overall type of intervention (i.e., control vs. PA‑
CAP38) (F=2336.422; df=1; p<0.00001) and time of incu‑
bation (i.e., 24 vs. 72 hours) (F=22.472; df=1; p=0.00032) 
were found to have a significant impact on the final 
outcome. A significant relationship was also found 
between time of incubation and type of intervention 
used  (F=22.133;  df=1;  p=0.00034).  Detailed post hoc 
comparisons show that PACAP38 up‑regulated BDNF 
mRNA expression in T98G cells significantly for both 
incubation times. The strongest stimulatory effect of 
PACAP38 was reported after 24‑hour incubation with 
peptide: a four‑fold up‑regulation of BDNF mRNA ex‑
pression was observed compared to the control group 
(p=0.00013). A 72‑hour incubation with PACAP38 main‑
tained neurotrophin levels at twice those of the control 
group (p=0.00013).  The  BDNF mRNA expression in the 
PACAP38 group significantly differed between 24 and 
72 hours (p=0.00018) (Fig. 2).
Effects of neuroleptics on BDNF release  
from the T98G cell line
The effects of haloperidol and olanzapine on the 
total extracellular BDNF levels in T98G cells was de‑
termined by ELISA assay. The cells were treated for 24 
and 72 hours with haloperidol and olanzapine, both 
at 5 µM (Fig. 3A) and at 20 µM (Fig. 3B). The results 
were analyzed using two‑way ANOVA, which confirmed 
that time of incubation had a significant impact on the 
final outcome at lower doses of haloperidol and olan‑
zapine  (F=223.596;  df=1;  p<0.000001). The type of in‑
tervention was also found to have a significant impact 
on  BDNF  content  (F=5.553;  df=2;  p=0.02686).  Detailed 
post hoc comparisons revealed that treatment with 
5 µM olanzapine (p=0.02368),  but  not  5  µM  haloperi‑
dol (p=0.29709),  significantly  increased  BDNF  release, 
irrespective of time of incubation. The concentration 
of BDNF was approximately 815 pg/ml in the control 
group; this value increased to 1051 pg/ml in the pres‑
ence of olanzapine and to 920 pg/ml in haloperidol 
(Fig. 3A). As the effect of interaction was found to be 
insignificant (F=2.647; df=2; p=0.12473) no further com‑
parisons were performed. 
After 24‑hour and 72‑hour treatment with 20 µM of hal‑
operidol and olanzapine, no statistically significant differ‑
ences in BDNF release were observed (Fig. 3B). 
Effect of PACAP38 on BDNF release  
from the T98G cell line
Because the strongest stimulatory effect on BDNF 
mRNA expression was reported with 1 µM PACAP 38, 
its effect on BDNF release was measured at different 
time periods: after 6, 12, 24, 48 and 72 hours (Fig. 4). 
Two‑way ANOVA confirmed that time of incubation had 
a significant impact on the final outcome (F=52.98; df=4; 
p<0.000001). A significant relationship was found be‑
tween time of incubation and type of intervention used 
(F=10.59; df=4; p=0.000006). Post hoc analysis found that 
the amount of BDNF released in the presence of PACAP38 
was significantly elevated compared to the appropriate 
control group, particularly at the 72‑hour time point 
(804 pg/ml vs. 982 pg/ml) (p=0.000150).  Interestingly, 
PACAP38 treatment was not found to have any effect on 
BDNF release after 12, 24 or 48 hours. The BDNF release 
in the PACAP38 group was also significantly greater at 
72 hours than at 24 hours (p=0.00025) or than 48 hours 
(p=0.00014) (Fig. 4). 
In this set of experiments, the BDNF content in the 
control group decreased over time; however, no such ef‑
fect was observed with the experiments conducted with 
neuroleptic drugs. 
Fig. 2. The effect of PACAP38 on BDNF expression in the T98G cell line. Cells 
were incubated with PACAP38 for 24 hours or 72 hours and subjected to 
gene expression studies. Control cells were treated with medium. 1 µg of 
total RNA isolated from cells was reverse transcribed and 50 ng of cDNA 
was used for the real-time PCR analysis. All real-time PCR reactions were 
performed in duplicate, using ACTB gene as an endogenous normalization 
factor. Results are expressed as relative units (r.u.) – a number resulting 
from the normalization procedure; values are given as mean ± SEM (n=8). 
Statistical differences are shown as *** at p<0.0005 vs. control and ### at 
p<0.0005 vs. 24 hours (Two-way ANOVA interaction: p<0.0005).
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Relationship between mRNA and protein 
expression of BDNF 
A positive correlation was observed between olanzap‑
ine‑induced changes in expression of BDNF at the mRNA 
and protein levels (R=0.6906; p=0.013) (Fig. 5A). While sim‑
ilar  changes  were  also  observed  for  PACAP38  (R=‑0.9553; 
p<0.0001) (Fig. 5B), the observed correlation is negative be‑
cause the BDNF mRNA expression was lower after 72 hours 
than after 24 hours of PACAP38 treatment.
DISCUSSION
As Shao et al. (2006) report that antipsychotics increase 
glial cell line‑derived neurotrophic factor (GDNF) secretion 
from rat C6 glioma cells, a trophic factor for dopaminergic 
neurons, the present paper examines the in vitro effects of 
neuroleptics on the expression of BDNF mRNA and protein 
release in a T98G human glioblastoma cell line, an astro‑
cyte‑like model.  Three  antipsychotic  drugs with  different 
mechanisms of action were chosen for the present study: 
one FGA, represented by haloperidol (a dopamine D2 – re‑
ceptor antagonist), and two SGAs, represented by olanzap‑
ine (a serotonin 5‑HT2A – receptor antagonist and a weak do‑
pamine D2 – receptor antagonist), and amisulpride (an atyp‑
ical neuroleptic drug which exhibits poor affinity for the se‑
rotonin 5‑HT2A – receptor). The T98G cells were exposed to 5 
and 20 µM concentrations of haloperidol and olanzapine or 
20 and 100 µM amisulpride and incubated for 24 or 72 hours. 
The choice of such concentrations was based on literature 
data (Lu and Dwyer, 2005, Shin and Song, 2014) and our own 
previous  cell  viability  measurements  (Jóźwiak‑Bębenista 
and Kowalczyk, 2017). Although these concentrations may 
seem high compared to the therapeutic plasma levels, they 
are similar to the concentrations of antipsychotic drugs 
(1–25 µM) that cause GDNF release from C6 cells (Shao at 
al, 2006) and to the concentrations of antidepressants 
(1–10 µM) that alter PACAP mRNA receptors in rat primary 
cortical neurons (Reichenstein et al. 2008). As gene expres‑
sion varies to a great degree over the time course of expo‑
sure to chemicals, a range of incubation times were chosen. 
Two incubation periods were chosen to demonstrate mRNA 
and  protein  changes:  The  first was  24  hours,  intended  to 
replicate short‑term treatment with drugs, which are only 
the initial event in cells, while a longer period of 72 hours, 
representing a long‑term treatment period limited by in vi-
tro studies, was intended to represent the delayed effect of 
Fig. 3. The effects of haloperidol and olanzapine on the BDNF content of conditioned media from cultured T98G cells. Cells were treated with haloperidol 
and olanzapine, 5 (A) and 20 (B) µM, for 24 and 72 hours. BDNF protein levels in cell-conditioned media were detected using a BDNF ELISA kit. Results are 
expressed as mean ± SEM (n=4-12). Statistical differences are shown as * at p<0.05 compared with the respective control value independently on time of 
incubation (Two-way ANOVA intervention: p<0.05).
Fig. 4. The effect of PACAP38 on the BDNF content of conditioned media 
from cultured T98G cells at various times of treatment. Cells were treated 
with PACAP 38, 1 µM, for 6, 12, 24, 48 and 72 hours. BDNF protein levels in 
cell-conditioned media were detected using a BDNF ELISA kit. Results are 
expressed as mean ± SEM (n=6). Statistical differences are shown as ** at 
p<0.005 and *** at p<0.0005 compared with respective control value and 
as ### at p<0.0005 vs. 24 hours or 48 hours (Two-way ANOVA interaction: 
p<0.0005).
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neuroleptic drugs. The T98G human cell line was used as an 
example of glial cells in the present in vitro study because of 
their functional similarity to normal astrocytes (Cabezas et 
al. 2015, Zabłocka et al. 2015). Studies show that glioblasto‑
mas express BDNF, and so may represent the stages of nor‑
mal astrocyte lineage (Xie et al. 2008).
In  our  study,  the  tested  antipsychotics  differentially 
regulated the mRNA expression of BDNF depending on the 
concentration and incubation time. After the short‑term 
treatment (24 hours) neither haloperidol nor olanzapine at 
a concentration of 5 µM exhibited any effect on the mRNA 
expression of BDNF. However, the chronic (72‑hour) treat‑
ment with the neuroleptics up‑regulated the levels of BDNF 
mRNA. After a 72‑hour incubation period, at a concentra‑
tion of 5 µM, haloperidol increased BDNF mRNA expression 
to 1.48 of the expression status while olanzapine increased 
it  to 1.54. Our findings  indicate  that  the  tested neurolep‑
tic drugs exert a potentially neuroprotective effect by in‑
creasing BDNF required time and repeating doses of drugs 
to develop. 
The results achieved in studies on the effects of neuro‑
leptics cannot be easily transferred from in vitro to in vivo, 
as the maximum duration of cell treatment is limited to 72 
to 96 hours and a typical treatment regimen with antipsy‑
chotics lasts from 10 to 50 years. Nevertheless, it is possible 
that  the effect observed  in  the present  study  in  the cells 
exposed to neuroleptic drugs for 72 hours may be related to 
the delayed effect observed in the animal and clinical stud‑
ies. It seems to be consistent with findings that the mech‑
anisms by which neuroleptics produce their therapeutic 
effects,  seen  after  a  few weeks  of  continuous  treatment, 
must involve the chronic regulation of a number of varied 
factors, like the appearance of neurotrophic factors fol‑
lowing the immediate receptor blockade (Chlan‑Fourney 
et al. 2002). It is possible that antipsychotics improve the 
symptoms of schizophrenia by altering the neuroplasticity 
of the affected neuronal pathways via the  long‑term reg‑
ulation of genes involved in the remodeling and survival 
of adult neurons, for instance by increasing BDNF expres‑
sion. The above findings correlate with pre‑clinical studies 
on BDNF levels in rodents: Chronic (19‑day) but not acute 
(45‑minute) antipsychotic administration altered the lev‑
els of hippocampal BDNF mRNA in male Wistar rats signifi‑
cantly (Chlan‑Fourney et al. 2002).
The next set of experiments examined whether the 
observed up‑regulation of BDNF mRNA expression by hal‑
operidol and olanzapine corresponded with the modifica‑
tion of protein level. It was found that both haloperidol and 
olanzapine at 5 µM concentration increased BDNF mRNA 
expression with similar efficacy after 72‑hour incubation. 
Exposure of T98G cells to 5 μM haloperidol or olanzapine 
for 72 hours increased BDNF concentration in the cul‑
ture medium by 13% and 29%, respectively. However, the 
up‑regulation of BDNF mRNA level by olanzapine alone cor‑
responded with  the  significantly  increased production of 
BDNF protein detected by ELISA. The observed differences 
in BDNF level might be related to the different therapeutic 
effects  of  FGAs  and  SGAs  in  patients with  schizophrenia. 
Our results correlate with previous in vivo studies showing 
that SGAs including olanzapine, clozapine, quetiapine and 
ziprasidone up‑regulated BDNF levels, whereas haloperidol 
(FGA) down‑regulates or does not affect BDNF  levels  (Bai 
et al. 2003, Park et al. 2006, 2009). Therefore, it can be sup‑
posed that the increased BDNF level caused by olanzapine 
may play a role in the neuroprotective mechanism of ac‑
tion of the tested drug in glial cells. BDNF, as the essential 
factor for the development of a number of glial properties, 
plays a key role in neuronal plasticity. Disturbances of the 
Fig. 5. Relationship between olanzapine and PACAP38-induced changes in mRNA and protein expression of BDNF in T98G cells in the 72-hour exposure 
period (A and B). The points represent the mRNA and protein gene expression data for olanzapine (5 μM) and PACAP38 (1μM), as well as the controls 
(dashed line: 95% confidence interval).
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regulatory neurotrophic factor in glial cells could repre‑
sent a major cause for neurological and psychiatric disor‑
ders. Therefore, the positive modulation of BDNF signaling 
may promote the normal state of astrocytes and support 
the protection and function of neuronal networks.
Surprisingly, haloperidol and olanzapine were not found 
to have analogous effects on BDNF mRNA level at a concen‑
tration of 20 µM. This higher concentration was found to 
have the opposite effect to lower concentration (5 µM) and 
caused a reduction of BDNF mRNA expression (especially 
after 24 hours of incubation). This demonstrates how the 
concentration of the drug affects the systems in the cell and 
shows how the secretion of BDNF is complicated and un‑
clear.  It  is  impossible  to draw any firm conclusions  about 
the clinical effects of haloperidol and olanzapine from our 
in vitro data because the doses of the neuroleptics we used 
were generally higher than those normally found in the 
brain tissue. Studies concerning antidepressants suggest 
that the negative effect on BDNF expression correlates with 
the simultaneous neurogenic and apoptotic processes of an‑
tidepressant drugs (Reichenstein et al. 2008). However, the 
concentration of neuroleptics used in this study was cho‑
sen on the basis of cell viability measurements: It was found 
that 20 µM was the highest concentration of haloperidol 
and olanzapine that did not exert any cytotoxic effect to‑
ward cells; this value was as high as 100 µM for amisulpride. 
Some antidepressant drugs are known to induce both 
a bi‑phasic and time‑dependent change in BDNF gene ex‑
pression (Coppell et al. 2006). This may also be the case 
with neuroleptics or, more likely, the effect of neuroleptics 
depends on their concentrations, and the lower concentra‑
tions of drugs used in the present study were effective in 
up‑regulating BDNF mRNA expression and protein. There 
are findings from dose‑response in vivo studies which sug‑
gest that lower doses of SGAs would upregulate hippo‑
campal BDNF mRNA expression while higher doses would 
downregulate it (Chlan‑Fourney et al. 2002). One explana‑
tion of this phenomenon may be the report by Kotani et 
al. (2006) that blockade or disruption of the cholinergic 
system down‑regulates BDNF. Olanzapine, an SGA, is a se‑
lective 5‑HT2A and D2 receptor antagonist; however, as with 
all such drugs, it loses its selectivity at higher concentra‑
tions and can demonstrate the same effects as FGAs, which, 
besides the intended blockade of dopamine receptors, can 
also  induce undesirable side effects by blocking choliner‑
gic, adrenergic and histaminergic receptors.
The second type of SGA tested in the present study was 
amisulpride. Similarly to 20 µM haloperidol, amisulpride 
mildly decreased BDNF expression to 0.81 of expression lev‑
els following a 72‑hour incubation at 20 µM. The observed 
effect  wasn`t maintained  by  100  µM  of  amisulpride  and, 
therefore, the production of BDNF protein was not iden‑
tified by ELISA. It has been shown that BDNF transcription 
is up‑regulated by neuroleptic drugs which block 5‑HT2A 
receptors in CNS (Vaidya et al., 1997). An example of this 
drug  is olanzapine. Amisulpride exhibits poor affinity  for 
the serotonin 5‑HT2A – receptor, and so probably does not 
exhibit a similar effect on BDNF as olanzapine. In turn, oth‑
er in vitro studies on SH‑SY5Y cells found amisulpride (1, 10, 
100 µM) to dose‑dependently increase the expression of the 
neuroprotective protein BDNF (Park et al. 2011). However, 
these results are not consistent with those of in vivo stud‑
ies which found no significant differences were revealed in 
BDNF serum levels in 47 patients with schizophrenia after 
six weeks of amisulpride treatment, compared to their lev‑
els at study entry. The interesting fact is that serum BDNF 
was significantly increased in the subgroup receiving olan‑
zapine compared to those treated with haloperidol, risper‑
idone or amisulpride (Rizos et al. 2010). It is likely that the 
effect of  given neuroleptics on BDNF expression may de‑
pend on  the  selectivity and/or pharmacodynamic profile 
of the drug.
Another aspect of the presented work was to compare 
the neuroprotective  effect  of neuroleptics with PACAP38, 
a peptide whose neuroprotective activity is known and well 
documented. Numerous findings provided by a number of 
research centers suggest that endogenous and exogenous 
PACAP, as well as its synthetic derivatives, demonstrate 
considerable  neuroprotective  and  anti‑inflammatory  po‑
tential, suggesting the possibility of their use as new ther‑
apeutic strategies for the treatment of neurological insults 
and psychiatric diseases, such as stroke (Chen et al. 2006), 
schizophrenia (Matsuzaki and Tohyama 2008) and depres‑
sion (Hashimoto et al. 2010). The mechanism of the neu‑
roprotective action of PACAP is complex, but studies in‑
dicate that is mediated, at least partly, by preventing the 
suppressed expression of BDNF (Frechilla et al. 2001, Ogata 
et al. 2015).
In  the  present  study,  PACAP38  significantly  up‑regu‑
lated BDNF mRNA expression in T98G cells. The strongest 
stimulatory effect of PACAP38, a four‑fold up‑regulation of 
BDNF mRNA expression compared to the control group was 
observed after 24‑hour incubation. A 72‑hour incubation 
with PACAP38 resulted in levels of neurotrophin elevated 
two‑fold compared to the control group (Fig. 2). The ele‑
vated levels of BDNF mRNA after 72‑hour incubation with 
peptide was  significantly  lower  than  the  effect  observed 
after 24 hours. It is possible that the repetitive prolonged 
treatment of cultured cells with PACAP38 may lead to the 
adaptive changes in BDNF expression following 72‑hour 
treatment. Georg and Fahrenkrug (2000) found PACAP38 
to have a similar effect on endogenous VIP gene transcrip‑
tion in the human neuroblastoma cell line, with the max‑
imal effect on VIP expression achieved following six‑hour 
incubation, followed by a steep decline after 24 hours from 
the initial treatment. The upregulation of BDNF transcript 
levels measured 24 hours after exposure to PACAP38 may 
reflect the inhibition of the degradation of existing BDNF 
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transcripts while the delayed long‑term up‑regulated 
BDNF mRNA levels may represent the activation of tran‑
scriptional mechanisms involving cAMP‑responsive el‑
ement‑binding protein (CREB) phosphorylation and the 
subsequent production of new BDNF transcripts. In order 
to confirm the observed changes in the mRNA expression 
of BDNF, a protein expression assay was performed. The 
results were coherent with those of the mRNA, and there 
was correlation between PACAP‑induced changes in the 
mRNA and protein expression of BDNF. BDNF release from 
T98G cells was observed after 72 hours of PACAP38 treat‑
ment (Fig. 4). 
In summary, of all the neuroleptic drugs tested in the 
present study, only olanzapine, similarly to exogenous PA‑
CAP38, increased the level of BDNF, which can contribute 
to  its neuroprotective mechanism of  action. Our findings 
offer a new insight  into the mechanism of action of anti‑
psychotics  (neuroprotective)  and  confirm  previous  find‑
ings that BDNF may represent the key target for PACAP and 
SGAs ‑ olanzapine. 
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